158 related articles for article (PubMed ID: 29617082)
1. Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study.
Demir M; Akin Y; Terim KAK; Gulum M; Buyukfirat E; Ciftci H; Yeni E
Int Braz J Urol; 2018; 44(3):600-607. PubMed ID: 29617082
[TBL] [Abstract][Full Text] [Related]
2. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Kyprianou N; Chon J; Benning CM
Prostate Suppl; 2000; 9():42-6. PubMed ID: 11056502
[TBL] [Abstract][Full Text] [Related]
3. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
4. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
[TBL] [Abstract][Full Text] [Related]
5. Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Alan C; Kırılmaz B; Koçoğlu H; Ersay AR; Ertung Y; Eren AE
Urology; 2011 Jun; 77(6):1439-43. PubMed ID: 21256572
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
Pande S; Hazra A; Kundu AK
Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
[TBL] [Abstract][Full Text] [Related]
8. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
9. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
10. Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A; Anoopkumar-Dukie S; Chess-Williams R; McDermott C
Prostate; 2016 Jun; 76(8):757-66. PubMed ID: 26880388
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the Pharmacodynamic Uroselectivity of
Quaresma BMCS; Pimenta AR; Santos da Silva AC; Pupo AS; Romeiro LAS; Silva CLM; Noël F
J Pharmacol Exp Ther; 2019 Oct; 371(1):106-112. PubMed ID: 31285236
[TBL] [Abstract][Full Text] [Related]
12. α-Blockers for benign prostatic hyperplasia: the new era.
Lepor H; Kazzazi A; Djavan B
Curr Opin Urol; 2012 Jan; 22(1):7-15. PubMed ID: 22080875
[TBL] [Abstract][Full Text] [Related]
13. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.
Shimizu S; Shimizu T; Tsounapi P; Higashi Y; Martin DT; Nakamura K; Honda M; Inoue K; Saito M
PLoS One; 2015; 10(8):e0133798. PubMed ID: 26308715
[TBL] [Abstract][Full Text] [Related]
14. Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia.
Yamada S; Kato Y; Okura T; Kagawa Y; Kawabe K
Biol Pharm Bull; 2007 Jul; 30(7):1237-41. PubMed ID: 17603160
[TBL] [Abstract][Full Text] [Related]
15. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.
Kyprianou N; Litvak JP; Borkowski A; Alexander R; Jacobs SC
J Urol; 1998 Jun; 159(6):1810-5. PubMed ID: 9598465
[TBL] [Abstract][Full Text] [Related]
16. Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume.
Paick JS; Cho MC; Song SH; Kim SW; Ku JH
J Korean Med Sci; 2008 Jun; 23(3):509-13. PubMed ID: 18583890
[TBL] [Abstract][Full Text] [Related]
17. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
Fonseca J; Martins da Silva C
Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
[TBL] [Abstract][Full Text] [Related]
18. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Araki T; Monden K; Araki M
Acta Med Okayama; 2013; 67(4):245-51. PubMed ID: 23970323
[TBL] [Abstract][Full Text] [Related]
20. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
